Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Delcath Systems, Inc. (DCTH) Announces First Use Of CHEMOSAT® Delivery System

|Includes: Delcath Systems, Inc. (DCTH)

Yesterday, Delcath Systems announced that the Delcath Hepatic CHEMOSAT® Delivery System has been used on first patients at the Johann Wolfgang Goethe University Hospital in Germany. The cases were treated as part of the initial launch and training agreement between Delcath and the hospital.

"Delcath's partnership with J.W. Goethe reinforces the potential of CHEMOSAT," said Eamonn P. Hobbs, president and CEO of Delcath. "We recently treated our first patients in Milan and are eager to continue our expansion across Europe. Opening another CHEMOSAT treatment center and treating patients in the continent's largest market is another step forward in the commercialization of this technology."

Two patients were treated for inoperable, liver-dominant metastases; one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications. Delcath is a pharmaceutical and medical device company that specializes in oncology. Delcath's proprietary systems administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, as well as control the systemic exposure of those agents to the body.

Dr. Thomas J. Vogl, Director of the Institute for Diagnostic and Interventional Radiology at J.W. Goethe, said, "We believe this technology has significant potential to help control cancers in the liver. We're pleased to be the first cancer center to begin offering this important treatment option to patients in Germany, and are eager to further explore its role in the treatment of multiple tumor types including breast cancer."

Delcath's initial focus is on the treatment of primary and metastatic liver cancers. The company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The CE mark allows the Company to market and sell the CHEMOSAT system in Europe. Delcath has not yet received FDA approval for commercial sale of its system in the United States; currently, the company is preparing for NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system.

For more information, please visit the company's website at www.delcath.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html